Showing results (191-200 of 210) with videos related to
Sort By:
Pageof 21
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 20, 2021
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III StudyShukui Qin, Jin Li, Yuxian Bai, et al.Journal of Hematology & Oncology|January 11, 2018
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJin Li, Shukui Qin, Jianming Xu, et al.Journal of Hematology & Oncology|September 6, 2017
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyXinyang Liu, Shukui Qin, Zhichao Wang, et al.Nature Communications|March 18, 2021
Long-distance electron transfer in a filamentous Gram-positive bacteriumYonggang Yang, Zegao Wang, Cuifen Gan, et al.Liver Cancer|June 16, 2023
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular CarcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.Frontiers in Pharmacology|March 9, 2026
Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter studyWeijia Jiang, Wanren Peng, Dong Qian, et al.Iscience|June 22, 2026
Ancient mitogenomes reveal the genetic relationship among extinct and extant water buffaloesXue-Yuan Liang, Xin-Meng Liu, Xiao-Le Lei, et al.Cancer Immunology, Immunotherapy : CII|January 3, 2025
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.Cancer Communications (London, England)|May 26, 2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialYuankai Shi, Jin Li, Jianming Xu, et al.Pageof 21